2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
08/16/16StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger
Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well as Other Conditions NEWARK, Calif. and YOKNEAM, Israel, Aug. 16, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) and Microbot Medical Ltd., a private company organized under the laws of the State of Israel (“Microbot”), today announced that they have entered into a definitive merger agreement, with plans to pursue the development of rob... 
Printer Friendly Version
05/31/16StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data
Company to Commence Orderly Wind Down of Operations NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).  While the results showed overall improvement in patients treated with the Company’s pr... 
Printer Friendly Version
05/10/16StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study
NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway™ Study later this month as part of the Company’s first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June. The ... 
Printer Friendly Version
05/06/16StemCells, Inc. Announces 1-for-12 Reverse Stock Split
NEWARK, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM),  announced today that at its annual stockholders meeting held on May 5, 2016, the Company's stockholders voted to approve a reverse stock split of the Company's common stock at a ratio of 1-for-12. Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, May 9, 2016, under the existing trading symbol "STEM" and a new CUSI... 
Printer Friendly Version
04/27/16StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV
NEWARK, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 – 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4. A live webcast of the presentation will be available through the Company's corporate website:... 
Printer Friendly Version
04/18/16StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal Cord Injury at ASIA Annual Meeting
Final Results for the First Six Patients to be Released Later this Quarter NEWARK, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, announced today that Dr. Stephen Huhn, the Company’s Chief Medical Officer and VP of Clinical Research, presented additional details on its ongoing Phase II Pathway™ Study of HuCNS-SC cells for the treatment of ... 
Printer Friendly Version
03/30/16StemCells, Inc., Pathway™ Study in Cervical Spinal Cord Injury Featured in The Downey Patriot
NEWARK, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced the company’s ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) was featured in an article published in The Downey Patriot. For the story entitled “Rancho Los Amigos partners with USC for groundbreaking stem cell research,” Christian Brown spoke wit... 
Printer Friendly Version
03/23/16StemCells, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update
Conference Call to be Hosted March 24, 2016, at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time) NEWARK, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, announced today that it will provide a business update and discuss financial results for the fourth quarter and year ended December 31, 2015, tomorrow, March 24, at 5:00 ... 
Printer Friendly Version
03/21/16StemCells, Inc. Announces Updated Timing for Webcast to Discuss Fourth Quarter 2015 Financial Results
NEWARK, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, announced today that it will host a conference call and webcast to discuss its results and an update on its business at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time) March 24. Interested parties are invited to listen to the call over the Internet by accessing the ... 
Printer Friendly Version
03/15/16StemCells, Inc. Announces Webcast to Discuss Fourth Quarter 2015 Financial Results
NEWARK, Calif., March 15, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, announced today that it will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Time (4:30 p.m. Eastern Daylight Time) March 23. Interested parties are invited to listen to the call over the Internet by accessing th... 
Printer Friendly Version
03/14/16StemCells, Inc. Announces Closing of $8 Million Public Offering
NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced that it has closed its previously announced offering of common stock and warrants. The Company sold a total of 26,667,000 shares of common stock, Series A warrants to purchase up to 13,333,500 shares of the Company’s common stock, and Series B warrants to purchase up to 20,000,250 shares of the Company’s common stock, at a public offering price of approximately $8 million. In addition, pursuant to ... 
Printer Friendly Version
03/09/16StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million
NEWARK, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced the pricing of an underwritten public offering of common stock, Series A Warrants and Series B Warrants with a public offering price of $0.30 for one share, a Series A Warrant to purchase 0.50 of a share of common stock and a Series B Warrant to purchase 0.75 of a share of common stock. The Company expects to receive gross proceeds of approximately $8.1 million, before deducting underwriting discou... 
Printer Friendly Version
03/08/16StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEWARK, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced that it intends to offer and sell common stock, Series A Warrants and Series B Warrants, subject to market and other conditions, in an underwritten public offering. The common stock, Series A Warrants and Series B Warrants are being offered under the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC).  The Company plans to file a regi... 
Printer Friendly Version
02/26/16StemCells, Inc., Pathway™ Study in Cervical Spinal Cord Injury Featured in Pittsburgh Post-Gazette
NEWARK, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced the company’s ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) was featured in an article published in the Pittsburgh Post-Gazette. ... 
Printer Friendly Version
02/04/16Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
NEWARK, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3rd Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Commun... 
Printer Friendly Version
01/28/16StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
StemCells, Inc. Was Voted the 2016 Winner “Buzz of BIO” Public Company NEWARK, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make presentations on the Company's programs, pipeline and operations at two upcoming conferences in February. The Company will be presenting at the 2016 BIO CEO Conference on Feb. 8 at 2:30 p.m. Eastern Standard Time at the Waldorf Astoria in New York City. StemCells, Inc. was recognized as the most inno... 
Printer Friendly Version
01/11/16StemCells, Inc. CEO Martin McGlynn Passes Baton to President and COO Ian Massey
Experienced Biotech Leader to Become Next Chief Executive Officer NEWARK, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced that Dr. Ian Massey, its President and Chief Operating Officer, has been appointed by the Board of Directors to succeed Martin McGlynn as the Company’s Chief Executive Officer, effective January 18, 2016. ... 
Printer Friendly Version
01/06/16StemCells, Inc. to Participate at the 8th Annual Biotech Showcase Investor Conference
Management Will Present an Update on the Company’s Programs, Pipeline and Operations NEWARK, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 8th Annual Biotech Showcase Investor Conference.  Management is scheduled to speak at 4:30 p.m. Pacific Standard Time on Monday, January 11, at the Parc 55 Hotel, located at 55 Cyril Magnin Street, San Francisco. A... 
Printer Friendly Version